Primary Biliary Cholangitis Market 2025

Primary Biliary Cholangitis Market Size

The global primary biliary cholangitis market reached a value of nearly $979.47 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.96% since 2019. The market is expected to grow from $979.47 million in 2024 to $1,499.06 million in 2029 at a rate of 8.88%. The market is then expected to grow at a CAGR of 8.73% from 2029 and reach $2,277.60 million in 2034. Growth in the historic period resulted from the increase in smoking, rising demand for personalized medicine, increase in liver transplantation awareness and increasing awareness and early diagnosis. Factors that negatively affected growth in the historic period was regulatory hurdles. Going forward, the increasing healthcare expenditure, growing geriatric population, surge in liver cancer and favorable government support will drive the growth. Factor that could hinder the growth of the primary biliary cholangitis market in the future include inadequate response to first-line treatment.

Primary Biliary Cholangitis Market Drivers

The key drivers of the primary biliary cholangitis market include: Increasing Healthcare Expenditure During the forecast period, the increasing healthcare expenditure is expected to propel the growth of the primary biliary cholangitis market. Higher healthcare spending drives pharmaceutical innovation, enhancing treatments and clinical research for primary biliary cholangitis. Increased budgets improve insurance coverage and reimbursement, making advanced therapies more accessible. Expanded healthcare infrastructure, including specialized centers and diagnostics, enables early detection and treatment, boosting patient adoption rates. For instance, according to the economic forecast from the office for budget responsibility (OBR) and treasury, planned health spending in the UK is expected to rise to £192 billion ($244.43 billion) in 2024/25 from £182 billion ($231.70 billion) in 2022/23. Additionally, according to national health expenditures accounts (NHEA) by KFF, a US-based independent source for health policy research, polling and journalism, health spending in the USA is expected to rise by 5% from 2023 to 2024, reaching $4.9 trillion. Therefore, the increasing healthcare expenditure will drive the growth of the primary biliary cholangitis market.

Primary Biliary Cholangitis Market Restraints

The key restraints on the primary biliary cholangitis market include: Inadequate Response To First-Line Treatment The inadequate response to first-line treatment is expected to hinder the growth of the primary biliary cholangitis market during the forecast period. Patients unresponsive to UDCA may need second-line therapies like obeticholic acid (OCA) or fibrates. However, high costs, side effects and insurance limitations can hinder adoption, restricting market expansion. Without accessible and effective alternatives, market growth may face significant obstacles, limiting overall demand and slowing industry progress. For instance, in December 2024, according to study published in the journal scientific reports, the ursodeoxycholic acid (UDCA) is the primary treatment for primary biliary cholangitis (PBC), however, it is not effective for all patients. Research suggests that up to 40% of individuals with primary biliary cholangitis exhibit an inadequate response to UDCA therapy. Therefore, the inadequate response to first-line treatment will restrain the growth of the primary biliary cholangitis market.

Primary Biliary Cholangitis Market Trends

Major trends shaping the primary biliary cholangitis market include: Role Of Combination Therapy In Liver Disease Management Major companies operating in the primary biliary cholangitis market are focusing on introducing innovative therapies such as combination therapy to enhance treatment efficacy and improve patient outcomes in liver cancer care. Combination therapy refers to the use of two or more treatments or drugs together to target a specific condition, enhancing the overall therapeutic effect. For example, in June 2024, Ipsen Biopharmaceuticals, Inc., a France-based biopharmaceutical company received U.S. Food and Drug Administration (FDA) approval for Ipsen's Iqirvo (elafibranor) 80 mg (miligram) tablets for treating primary biliary cholangitis (PBC). This drug is a first-in-class PPAR (peroxisome proliferator-activated receptor) treatment. It is intended for use in combination with ursodeoxycholic acid (UDCA) for adults who do not respond adequately to UDCA, or as a monotherapy for patients who cannot tolerate UDCA. Advancements In Bile Acid Analog-Based Therapies Major companies operating in the primary biliary cholangitis market are focused on developing innovative and specialized treatments, such as orphan drugs with a combination of obeticholic acid (OCA) and bezafibrates to treat primary biliary cholangitis (PBC). This combination aims to provide a more effective approach to managing PBC while securing market exclusivity. By integrating OCA, a bile acid analog, with bezafibrate, a PPAR (Peroxisome Proliferator-Activated Receptors) agonist, these treatments have the potential to improve patient outcomes and quality of life. For instance, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, received orphan drug designation from the FDA for the OCA-bezafibrate combination as a potential therapy for PBC, a progressive liver disease. Additionally, obeticholic acid, marketed as Ocaliva, is already approved for PBC treatment in the US.

Opportunities And Recommendations In The Primary Biliary Cholangitis Market

Opportunities – The top opportunities in the primary biliary cholangitis market segmented by treatment type will arise in the drugs segment, which will gain $511.63 million of global annual sales by 2029. The top opportunities in the primary biliary cholangitis market segmented by diagnosis will arise in the liver tests segment, which will gain $139.56 million of global annual sales by 2029. The top opportunities in the primary biliary cholangitis market segmented by end user will arise in the hospitals segment, which will gain $247.45 million of global annual sales by 2029. The primary biliary cholangitis market size will gain the most in the USA at $130.97 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the primary biliary cholangitis companies to focus on combination therapy to improve treatment outcomes, focus on orphan drug development using OCA-bezafibrate combinations, focus on drug development to drive market growth, focus on liver tests to maximize diagnostic market growth, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for drug development and commercialization, provide competitively priced offerings, continue to use B2B promotions and focus on specialty clinics to capture high-growth end-user demand.